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Abstract: Background: Neoadjuvant therapy (NAT) represents a paradigm shift in the management
of patients with pancreatic ductal adenocarcinoma (PDAC) with perceived benefits including a
higher R0 rate. However, it is unclear whether NAT affects the sites and patterns of recurrence
after surgery. This review seeks to compare sites and patterns of recurrence after resection between
patients undergoing upfront surgery (US) or after NAT. Methods: The EMBASE, SCOPUS, PubMed,
and Cochrane library databases were systematically searched to identify eligible studies that compare
recurrence patterns between patients who had NAT (followed by resection) with those that had
US. The primary outcome included site-specific recurrence. Results: 26 articles were identified
including 4986 patients who underwent resection. Borderline resectable pancreatic cancer (BRPC, 47%
1074/2264) was the most common, followed by resectable pancreatic cancer (RPC 42%, 949/2264).
The weighted overall recurrence rates were lower among the NAT group, 63.4% vs. 74% (US)
(OR 0.67 (CI 0.52–0.87), p = 0.006). The overall weighted locoregional recurrence rate was lower
amongst patients who received NAT when compared to US (12% vs. 27% OR 0.39 (CI 0.22–0.70),
p = 0.004). In BRPC, locoregional recurrence rates improved with NAT (NAT 25.8% US 37.7% OR
0.62 (CI 0.44–0.87), p = 0.007). NAT was associated with a lower weighted liver recurrence rate
(NAT 19.4% US 30.1% OR 0.55 (CI 0.34–0.89), p = 0.023). Lung and peritoneal recurrence rates did not
differ between NAT and US cohorts (p = 0.705 and p = 0.549 respectively). NAT was associated with a
significantly longer weighted mean time to first recurrence 18.8 months compared to US (15.7 months)
(OR 0.18 (CI 0.05–0.32), p = 0.015). Conclusion: NAT was associated with lower overall recurrence rate
and improved locoregional disease control particularly for those with BRPC. Although the burden of
liver metastases was less, there was no overall effect upon distant metastatic disease.
Keywords: recurrence; neoadjuvant chemotherapy; pancreatic ductal adenocarcinoma; pancreatic
surgery
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1. Introduction
Patients who have undergone potentially curative treatment for pancreatic ductal adenocarcinoma
(PDAC) typically suffer treatment failure with cancer recurrence [1], frequently within two years of
resection [2]. Recurrence, including multi-site recurrence and liver metastases, are key prognosticators
of overall survival [3]. Several risk factors for specific recurrence patterns have been identified. Positive
resection margin and poor tumour differentiation [2,4] are risk factors for locoregional recurrence.
Tumour size, elevated preoperative Ca19-9 serum level, and perineural invasion are risk factors for
distant recurrence [5].
While upfront surgery followed by adjuvant therapy has been the standard of care for PDAC, this
is being challenged by recent evidence with use of neoadjuvant chemotherapy (NAT) for borderline
resectable pancreatic cancer (BRPC) [6] and resectable (RPC) [7] pancreatic cancer (LAPC) [8]. It is
important to determine the impact of different treatment strategies on pattern of disease recurrence [9,10].
NAT is associated with a higher rate of achieving R0 margins [11,12] and may control micrometastatic
disease; thus, it is important to determine whether NAT influences patterns of treatment failure in
terms of the frequency and site of recurrent cancer.
While here have been meta-analyses examining the impact of NAT on overall survival [13,14],
there is paucity of evidence examining the impact of NAT and upfront surgery (US) on disease
recurrence and recurrence patterns with and without neoadjuvant chemotherapy.
This present study aimed to undertake a meta-analysis of available evidence to compare patients
with PDAC undergoing upfront surgery versus neoadjuvant therapy followed by surgery to review
sites of recurrence, recurrence-free survival patterns, overall recurrence rate, and time to recurrence in
patients with resectable, borderline resectable and locally advanced pancreatic cancer.
2. Materials and Methods
The protocol of this review was registered on the Prospero database prior to inception
(CRD42019159031).
2.1. Literature Search
The EMBASE, SCOPUS, PubMed and Cochrane library databases were systematically searched
with the aid of a pre-devised literature search strategy that followed the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15]. Details of the query string
with accompanying Boolean operators are reported in Appendix A. Limits were set to English studies
reported from January 2000 to February 2020 in human patients. Reference lists of included studies
were then examined by two authors (C.B.B.R. and A.Y.S.) to identify eligible studies missed by the
original search strategy.
2.2. Data Selection, Extraction, Risk of Bias Assessment and Publication Bias Assessment
Studies were included in the quantitative meta-analysis if they reported comparative recurrence
outcomes specific to patients who underwent NAT compared to those undergoing US for PDAC. More
specifically, if they reported overall recurrence, time to first recurrence, sites of recurrence and/or
recurrence free survival (RFS). Studies were excluded if they were case reports/series, conference
abstracts, study protocols, non-comparative observational cohorts, did not report recurrence or RFS
data for either NAT or upfront surgery patients, did not employ NAT, and articles published prior to
2000. Title, abstract and full text screening were performed by two investigators (C.B.B.R. and A.Y.S.).
Consistency of data extraction was compared, and disputes were adjudicated by a third author (S.P.).
Baseline characteristic data including: age; gender; location of tumour; preoperative tumour stage and
resectability; details of NAT data; preoperative radiotherapy; adjuvant therapy; pathological outcome
data including; nodal status; tumour differentiation; tumour size; perineural/lymphovascular invasion;
R0 resection; and patterns of recurrence including overall recurrence rate, time to first recurrence, site
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of recurrence, and RFS. The primary outcome was site-specific recurrence. The secondary outcomes
were overall recurrence, time to first recurrence, and recurrence-free survival.
2.3. Assessment of Study Quality
The risk of bias and study quality assessment was performed through use of the methodological
index for non-randomized studies (MINORS) grading criteria [16] for non-randomised studies.
The Cochrane’s risk of bias tool [17] was used for randomised controlled trials. Publication bias was
identified through visual inspection of funnel plots whereby bias existed if individual studies lay
beyond the funnel limits.
2.4. Terminology and Definitions
NAT included preoperative chemotherapy with or without radiotherapy. Sole radiotherapy-based
NAT regimens were not assessed in this meta-analysis. Fluoropyrimidine-based chemotherapies
included S-1 (5-fluorouracil prodrug tegafur with oteracil, and gimeracil) [18], capecitabine and
5-fluorouracil; platinum-based chemotherapies included cisplatin and oxaliplatin; and plant alkaloids
included docetaxel and paclitaxel. FOLFIRINOX was a combination regime of 5-fluorouracil,
leucovorin, oxaliplatin, and irinotecan. If an agent was used in combination with another, this was
considered combination chemotherapy. Upfront surgery (US) included all forms of pancreatic resection
(including pancreatoduodenectomy, distal pancreatectomy and total pancreatectomy) performed
shortly after the diagnosis of a pancreatic cancer without preoperative NAT. The authors identified
resectable (RPC), borderline resectable (BRPC), and locally advanced (LAPC) when reported as such.
The definitions of these categories were variably reported and have changed over the course of the
study with the publication of multiple definitions [19–21]. Nodal status was considered N0 when
there were no positive nodes at the time of surgery. Tumour differentiation was based on histology
of the specimen following resection [22] and tumour size by the largest diameter reported by the
pathologist. Presence of malignant cells in neural tissue or lymphovascular tissue denoted perineural
or lymphovascular invasion [23]. R0 resection was defined when there was no microscopic tumour
present within 1 mm of the resection margin [24]. Recurrence patterns included overall recurrence
rates, time to first recurrence and recurrence-free survival rates. Overall recurrence was defined by
the first presentation of previously unknown disease activity during postoperative follow-up [25].
Locoregional recurrence was the presence of tumour recurrence at the site of previous resection or in
surrounding lymph nodes (LN). Distant recurrence referred to recurrence present in distant organs.
RFS rate was defined as the proportion of patients who had no confirmed recurrence of cancer and
included the terms progression-free survival and disease-free survival [26]. Time to first recurrence
represented the interval following resection that the first recurrence of disease was observed and was
calculated by the mean RFS [27]. Disease-specific survival [28,29] or cancer-specific survival [8] were
not included in this analysis as these terms focused solely on survival secondary to the cancer.
2.5. Statistical Analysis
The meta-analysis was conducted in its entirety with the packages: tidyverse [30], meta [31],
metaphor [32], and MetaAnalyser (Jack Bowden and Christopher Jackson, UK) [33] in R project
(R Foundation for Statistical Computing, Austria 2014). A Mantel-Haenszel model was utilised
to perform the pairwise meta-analysis. The output was reported as odds ratios (OR) or standard
mean difference (SMD) with 95% confidence intervals (CI). I2 test allowed the authors to determine
statistical heterogeneity whereby a threshold of 50% suggested moderate heterogeneity and 75%
indicative of substantial heterogeneity [34]. Weighted means and recurrence rate estimates with their
corresponding 95% CI were calculated for age, tumour diameter, follow-up interval, and recurrence
outcomes. Weighted means were calculated by the inverse variance method. Weighted recurrence rate
estimates were determined by a random intercept logistic regression model [31]. Weighted estimates
were only calculated when three or more datapoints were available. WebPlotDigitizer (Ankit Rohatgi,
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CA, USA, 2019) [35] was employed to extract raw data from reported Kaplan Meier survival curves
if articles failed to provide raw numbers for RFS or time to first recurrence. The median (1st and
3rd quartile) time to first recurrence was only calculable from a Kaplein Meier curve if both survival
curves crossed the 75% and 25% survival threshold. Mean estimates were then derived from median
and ranges or quartiles through Wan et al. [36].
Propensity score matched data was used in preference to raw unmatched data to improve
homogeneity of the datasets in relevant studies [8,27,37,38]. However, if baseline characteristic
data or outcome data were not reported for propensity score matching, the unmatched data was
used [28]. Historic [25] or unpublished [39] US cohorts were utilised if baseline characteristics were
reported. Data for baseline characteristics was commonly reported for the entire study population
irrespective of those who subsequently underwent resection. However, the remaining outcomes
including pathological, resectability and recurrence data are reported for the population who ultimately
underwent surgery and were subsequently followed-up. When calculating NAT agent-specific time to
first recurrence, the authors included situations where the agent was used as the base NAT, used in
combination with another agent or used in more than 30% of the cohort [40]. Recurrence outcomes
were reported with significantly fewer patients than in the pathological and resectability outcomes in
another study [41] and this is reflected in the meta-analysis.
3. Results
From 3933 potentially relevant studies, 22 were included in the quantitative analysis.
Four additional studies [8,40,42,43] were recruited into the meta-analysis following a review of
the reference lists of the 22 studies (Figure 1).
Figure 1. PRISMA flow chart of literature search strategy.
Among 4986 patients, 1699 received NAT followed by pancreatic resection (34%, 1699/4986) and
3287 patients US (66%, 3287/4986). The studies were from predominantly single centers (81%, 21/26) in
Asia (42%, 11/26) and retrospective in design (81%, 21/26) (characteristics of all studies are summarised
in Table 1).
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Table 1. Characteristics of all included studies and patients recruited into the meta-analysis for quantitative analysis.
Author Publication
Year
Country Study Type
(n)
Recruitment
Dates
Centres (n)
Total Study
Population
(n)
Cohorts Undergoing
Surgery for Comparison
Total in
Quantitative
Analysis (n)NAT (n) US (n)
Versteijne et al. [44] 2020 Netherlands Trial 2013–2017 16 246 72 92 164
Lof et al. [37] 2019 Europe Retrospective 2007–2015 Multiple 1236 94 * 94 ± 188
Yoshiya et al. [26] 2019 Japan Retrospective 2008–2018 1 20 11 9 20
Groot et al. [25] 2019 USA Retrospective 2007–2015 1 1188 231 95 * 1188
Nagakawa et al. [38] 2019 Japan Prospective 2011–2013 63 884 223 27 * 500
Nurmi et al. [27] 2018 Finland Retrospective 2000–2015 1 225 75 150 * 225
Jang et al. [7] 2018 Korea Trial 2012–2014 4 40 17 18 35
Chen et al. [8] 2017 China Retrospective 2004–2013 Multiple 196 98 98 * 196
Masui et al. [45] 2016 Japan Prospective 2005–2010 1 37 15 19 34
Ferrone et al. [43] 2015 USA Retrospective 2011–2014 1 127 40 87 127
Fujii et al. [28] 2015 Japan Retrospective 2002–2014 1 92 18 50 68
Ishikawa et al. [46] 2015 Japan Retrospective Until 2011 1 506 112 238 350
Golcher et al. [47] 2014 Germany Trial 2003–2009 1 66 33 33 66
Papavasiliou et al. [41] 2014 USA Retrospective 1990–2009 1 309 108 201 309
Cho et al. [48] 2013 Korea Retrospective 2002–2011 1 51 30 21 51
Jiang et al. [40] 2013 China Retrospective 2004–2010 1 232 11 β 120 232
Kang et al. [6] 2012 Korea Retrospective 1999–2010 1 136 32 104 136
Tajima et al. [49] 2012 Japan Retrospective 2006–2009 1 34 13 21 34
Barugola et al. [29] 2012 Italy Retrospective 2001–2008 1 403 41 362 403
Katz et al. [50] 2012 USA Retrospective 2004–2008 1 147 147 47 194
Barbier et al. [51] 2011 France Retrospective 1997–2006 1 173 38 67 105
Sahora et al. [39] 2011 Asutria Retrospective 2003–2006 1 106 13 73 ¥ 86
Greer et al. [52] 2008 Lebanon Retrospective 1993–2005 1 102 42 41 € 83
Massucco et al. [42] 2006 Italy Retrospective 1999–2003 1 72 8 44 52
Moutardier et al. [53] 2004 France Retrospective 1997–2002 1 87 23 17 40
Pingpank et al. [54] 2001 USA Retrospective 1987–2000 1 100 53 47 100
NAT Neoadjuvant therapy; US Upfront surgery; * Propensity score matched data; € Did not include operation alone as specific outcomes were not reported for this; ± Historical cohort;
¥ Unpublished cohort; β Included both neoadjuvant chemotherapy (n = 81, 72%)and neoadjuvant radiotherapy alone (n = 31, 28%) as outcomes were reported for overall NAT cohort.
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Baseline characteristic data was reported for all patients initially recruited into the studies
before NAT was administered (n = 5328). Patients were commonly female (54%, 2885/5328) in their
seventh decade of life (weighted mean age 62 years, CI 60.4–63.6). Tumour location was reported
in 20 studies [6–8,26,29,37–42,44,45,47–51,53,54] and was predominantly the pancreatic head or neck
(79%, 2478/3147) (Table S1).
3.1. Neoadjuvant and Adjuvant Therapy
Most patients received Gemcitabine-based NAT (24 studies [6–8,25–29,39–54], 62%, 851/1382).
Fluoropyrimidines (20%, 282/1382) and FOLFIRINOX (13%, 182/1382) based regimens were not
uncommon, however, platinum-based and plant alkaloid regimens were rare (7% 97/1382 and 2%
23/1382 respectively) (Table S3). Combination therapy was also observed in 23% (312/1382). Preoperative
radiotherapy was a component of NAT in 51% (868/1699) patients. A minority of patients in a single
study undergoing solely radiotherapy as the NAT regime (28%, 31/112) [40] was included under NAT
cohort as outcomes were reported for all patients.
Adjuvant therapy was reported in 14 studies [7,25–28,37,41,42,44,45,47,48,51,52] and was
received by 66% of patients (1649/2505). This included either chemotherapy (61%, 1011/1649)
or chemoradiotherapy (39%, 638/1649). In one study [52], only those with adjuvant therapy vs.
neoadjuvant was compared and those with US without adjuvant therapy were excluded as outcomes
were not reported.
3.2. Resection and Resectability in the NAT Cohort
Following NAT, 1699 proceeded to resection (87%). Failure to proceed to resection was due to
cancer progression during NAT (35%, 86/243) or severe NAT toxicity leading to disruption of therapy
(11%, 27/243). However, the indication for non-operative management was not reported in 53% of
patients (130/243, Figure 2). The indication for resection among BRPC and LAPC was reported in nine
studies. BRPC was included for resection in patients with the superior mesenteric artery (SMA) or
superior mesenteric vein (SMV) involvement not exceeding 180 degrees in six studies [28,38,43,45,51,52]
and without tumour extension in the celiac axis unless considered safe for complete resection in two
studies [28,38]. Those without SMA involvement and < 180-degree involvement of SMV was the criteria
for resection in one study [29]. LAPC was considered resectable in patients with common hepatic
artery, root of splenic artery or celiac axis involvement in one study [26], and SMA or coeliac axis (CA)
involvement with stenosis or thrombosis of the vessel in another study [42]. Four studies [6,7,25,28]
defined BRPC by the national cancer network guidelines [55]. The types of resection were reported
in 17 studies [6,8,25,26,28,29,37,40–43,45,48–51,53]: pancreaticoduodenectomy (PD, including pylorus
preserving variant, 79%, 2639/3344), distal pancreatectomy (17%, 564/3344), and total pancreatectomy
(4%, 141/3344).
The preoperative tumour resectability for all patients undergoing resection was reported in
17 studies [6–8,26–29,38,41,43,45,47–50,52,53] for NAT and US groups. BRPC were the most prevalent
(47%, 1074/2264), followed by RPC (42%, 949/2264) and locally advance pancreatic cancer (LAPC)
(10%, 230/2264). In the NAT group, 15% (131/866) were LAPC, 23% (203/866) RPC, and 60% (522/866)
were BRPC. In the US group, 7% (99/1398) were LAPC, 39% (552/1398) BRPC, and 53% were (746/1398)
RPC. Eleven patients had unresectable tumours that subsequently underwent resection in three
studies [26,42,52] (NAT 10/866, US 1/1398, Table S3).
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Figure 2. Flow chart of patient management and overall recurrence for patients initially allocated to
neoadjuvant therapy (NAT) and upfront surgery.
3.3. Primary Outcome Measure
Sites of Recurrence
The weighted locoregional recurrence rate was lower amongst patients receiving NAT first, 12%
and 27% (Figure 3A) in patients under NAT and US, respectively (OR 0.39 (CI 0.22–0.70); p = 0.004,
Figure 4A) in 16 studies [7,25,28,38,40–43,45,46,49–54]. On subgroup analysis of all studies published
after 2010, consistent improvement in locoregional recurrence with NAT was observed (p = 0.014,
Figure 4A). The weighted locoregional recurrence rate in BRPC undergoing resection was also improved
with NAT (NAT 25.8% (CI 20.9–31.2), Figure 3B) compared to US (US 37.7% (CI 30.4–45.4) OR 0.62
(CI 0.44–0.87), p = 0.007) in four studies [7,28,38,45]. The locoregional recurrence rate for RPC in
the US was 11.9% (CI 7.5–17.1) in four studies [42,43,49,53]. This analysis could not be compared
for RPC in the NAT group due to being only reported in two studies [49,53]. NAT was associated
with a lower weighted liver recurrence rate (19.4% CI 13.4–27.2) compared to US (30.1% CI 22.7–38.7
Figure 3A) (OR 0.55 (CI 0.34–0.89), p = 0.023, Figure S4A) in eight studies [7,25,28,40,41,43,46,49].
Weighted lung and peritoneal recurrence rates did not differ between NAT and US cohorts (p = 0.705
and p = 0.549 respectively, Figure 3A and Figure S4B,C), and the overall rate of distant recurrence was
similar between NAT and US in 13 studies [7,25,28,38,40,42,43,45,46,49–51,53] (NAT 46%, 463/997 US
51% 1003/1962, OR 0.92 (CI 0.61–1.39), p = 0.664, Figure 4B). Similarly, no difference was observed on
subgroup analysis of studies published following 2010 (Figure 4B).
Similar weighted rates of distant recurrence were observed for BRPC in the NAT (NAT 50.9%
CI 38.8–62.8) and US groups (US 54.7% CI 38.7–70.2), Figure 3B) in four studies [7,28,38,45]. The rate
of distant recurrence for RPC in the US was 36.6% (CI 19.6–55.5) in four studies (Figure 3B). Again,
this could not be compared to RPC in the NAT group as this was only reported in two studies [49,53].
The most common site of recurrence was the liver for BRPC and RPC in the US (21% 280/1342 and 53%
114/216 respectively) and NAT (9% 49/534 and 28% 65/231 respectively) groups in six [7,25,28,38,45,48]
and five studies [42,43,49,50,53], respectively. The remaining distribution of resectability-specific organ
sites were infrequently reported. On subgroup analysis of six studies [7,28,38,45,49,53] reporting
cohorts comprised solely of BRPC or RPC, no significant differences were found for locoregional
(p = 0.166) and distal recurrence rates (p = 0.786) (Figure S1A,B).
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Figure 3. Weighted estimates of: (A) Site-specific rates of recurrence; (B) Resectability-specific sites
of recurrence; (C) NAT-specific rates of distant organ-specific recurrence; (D) NAT-specific time to
first recurrence. Ninety-five percent confidence intervals are denoted by the central bar. Neoadjuvant
therapy (NAT); Up-front Surgery (US); Borderline resectable pancreatic cancer (BRPC); resectable
pancreatic cancer (RPC).
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Figure 4. Forest plot showing: (A) locoregional (n) and (B) distal recurrence rates (n) following
neoadjuvant therapy (NAT) vs. up-front Surgery (US). The results of a subgroup analysis of all articles
published after 2010 are also shown. A Manel–Haenszel random effects model with a Hartung–Knapp
adjustment was used for the meta-analysis of all outcomes. A Sidik–Jonkman estimator was utilised
for tau2. Odds ratios (OR) are shown with 95 percent confidence intervals (CI).
Site-specific recurrence was reported in at least three articles for both gemcitabine [6,40,45,49,50]
and fluoropyrimidine [40,45,49,51], whereby liver recurrence was the most frequent and the distribution
of organ-specific weighted recurrence rates were similar between both agents (Figure 3C). Comparisons
of recurrence between different chemotherapeutic agents were not reported.
3.4. Secondary Outcome Measures
Overall Recurrence
The weighted mean follow-up interval for recurrence outcomes was 40.8 months (CI 33.4–48.1).
During this interval, the absolute overall recurrence rate for the entire cohort was 70%
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(2345/3351, Figure 2) reported in 16 studies [7,25,28,38,40–43,45,46,49–54]. The weighted overall
recurrence rate was 63.4% (CI 51.8–73%) for NAT, significantly lower than the 74% (CI 68.7–80%)
weighted overall recurrence rate of the US cohort (OR 0.67 (CI 0.52–0.87), p = 0.006, Figure 5A).
On subgroup analysis of RPC, consistent improvement in weighted overall recurrence rates with
NAT was observed in five studies [42,43,49,50,53] (NAT 50% 115/231, US 56% 122/216, OR 0.68
(CI 0.50–0.94), p = 0.029). However, for BRPC, similar weighted overall recurrence rates between
NAT and US were observed on subgroup analysis of six studies [7,25,28,38,45,48] (NAT 75% 400/534
US 80% 1068/1342, OR 0.61 (CI 0.28–1.31), p = 0.158, Figure S3A). The presence or absence of
preoperative chemo radiotherapy in the NAT cohort did not impact the significant difference in
weighted overall recurrence rate (with preoperative chemoradiotherapy 66% (CI 54.6–75.8) and
without 68.9% (CI 53.4–81), Figure S3B). On meta-regression, borderline resectability, perineural
invasion and N0 nodal status were independent predictors of overall recurrence (Table S4).
Figure 5. Forest plot showing: (A) overall recurrence rates (n) and (B) time to first recurrence
(months) following neoadjuvant therapy (NAT) vs. up-front Surgery (US). A Manel-Haenszel random
effects model with a Hartung–Knapp adjustment was used for the meta-analysis of all outcomes.
A Sidik–Jonkman estimator was utilised for tau2.
3.5. Time to First Recurrence
NAT was associated with a significantly longer weighted mean time to first recurrence (18.8 months,
CI 14.5–23.5) compared to US (15.7months, CI 12.2–19.2) in nine studies [6,26,27,37,39–41,45,47] (OR 0.18
(CI 0.05–0.32), p = 0.015, Figure 5B). Fewer than three studies reported resectability-specific time to first
recurrence in both the US and NAT groups and no study reported organ-specific time to first recurrence.
The weighted time to first recurrence for each specific NAT agent ranged from 18.5–22.9 months
(Figure 3D). The weighted time for each individual agent was calculated from studies using that
specific NAT as the base or in combination with another agent. Two studies were excluded in the
meta-analysis of time to first recurrence as outliers significantly skewed mean estimates for the US
cohort [51] and the significant discrepancy in cohort numbers made the output uninterpretable [25].
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3.6. Recurrence-Free Survival
The weighted RFS rate at 2 and 5 years was 40.5% (CI 29.8–52.2%) and 22.2% (CI 9.2–44.5%)
in the NAT cohort and 24.9% (CI 17.7–33.9%) and 13.4% (CI 7.8–22.1%) in the US respectively.
NAT was associated with a significantly higher RFS rate at both time points (Two year: OR
1.79 (CI 1.23–2.61), p = 0.005 and Five year: OR 1.95 (CI 1.03–3.69), p = 0.043 respectively)
(Figure S2) in 15 [26,28,29,37,39–42,44,45,47–50,52] and 9 studies [8,29,40,41,45,47,48,50,52] respectively.
One study [44] only reported 2-year RFS data for those who began NAT but not specific to those who
ultimately underwent resection.
3.7. Meta-Analysis of Pathological Outcomes between NAT and Upfront Surgery
The post-resection pathology is summarised in Table S2. NAT was associated with a
smaller tumour diameter (SMD-0.67 (CI 1.05–0.28), p = 0.002, Figure S5). This correlated with
a lower rate of perineural invasion in 12 studies [6,25,27,28,37,41–45,49,51] (NAT 53%, 392/744
US 80% 1504/1886, OR 0.30 (CI 0.18–0.49), p < 0.001, Figure S6B), lymphovascular invasion in
14 studies [6,7,25–28,37,38,43–45,48,49,51] (NAT 43%, 394/909 US 52%, 1014/1966, OR 0.50 (CI 0.25–0.98),
p = 0.044, Figure S6C), higher rates of N0 nodal status in 21 studies [6–8,25–29,37,38,41–50,53] (NAT 58%,
840/1441 US 29% 847/2939, OR 3.36 (CI 1.93–5.84), p < 0.001, Figure S7A) and higher rates of R0 resection
in 22 studies [6,7,25–29,37,38,40–45,47–51,53,54] (NAT 78%, 1120/1434 US 67% 1909/2837, OR 1.86
(CI 1.27–2.71), p = 0.003, Figure S7B) compared to those undergoing US. However, comparable
rates of poor tumour differentiation in 11 studies [6,8,25,27–29,40–42,45,50] (p = 0.494, Figure S6A)
were observed.
3.8. Heterogeneity and Risk of Bias
Moderate heterogeneity was found in the outcomes to assess locoregional and distant recurrence
rates. Moderate heterogeneity was further reported for liver recurrence and 2- and 5-year RFS.
The pathological outcomes of tumour diameter, rates of lymphovascular involvement, and N0 nodal
status also observed marked heterogeneity in the dataset. Overall, the non-randomised studies scored
poorly in the MINORS criteria (Median 13 Range 11–19). Significant deficiency with regards to
unbiased prospective data collection, blinded assessment of outcomes, and power calculations were
seen globally (Table S5A). Many studies also failed in the domain of equivalent baseline characteristics
(n = 12) [6,25,26,28,39,41–43,46,50,52,54]. Cochranes risk of bias tool also identified obvious deficits
in the three randomized controlled trials (RCTS) [7,44,47] in the domains of blinding of participants
and outcomes, which is an obvious consequence of the nature of the disease (Table S5B). Significant
publication bias was observed on visual inspection of Forest plots for the outcomes of tumor diameter,
N0 nodal status, and lymphovascular invasion (Figure S8).
4. Discussion
Recurrence after pancreatic resection for PDAC is frequent with 20% of patients developing
recurrence within 6 months and a further 40% in the first year of resection in spite of a margin-free
resection [56]. Even among those who complete adjuvant therapy, median overall survival remains less
than 20 months [57,58]. Recent chemotherapeutic regimens such as FOLFORINOX and Gemcitabine
plus Nab-paclitaxel have shown favourable results in improving resectability even in patients with
LAPC with resection rates ranging between 0–40% [59]. However, there is paucity of level 1 evidence
regarding the role of NAT on recurrence patterns for resectable and BRPC. Two recent RCTs explored
the role of NAT in resectable and BRPC. Jang et al. in a recent phase 2/3 RCT comparing neoadjuvant
chemo radiation with gemcitabine versus upfront resection in patients with BRPC showed comparable
over all recurrence rates and recurrence patterns. On the contrary, the Dutch PREOPANC phase III
randomised controlled trial comparing preoperative chemo radiotherapy versus upfront surgery for
resectable and BRPC showed improved disease-free survival in the NAT group although the time to
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recurrence and recurrence patterns were not fully evaluated. The present review of 26 studies including
4986 patients has shown that NAT was associated with lower overall recurrence rates (63% vs. 74%),
lower loco-regional recurrence rates (12 vs. 27%), and particularly in patients with BRPC. NAT was
associated with a lower liver recurrence rate (19.4 vs. 30.1%) and improved recurrence-free survival
at 2 years (40.5% vs. 24.9%) and 5 years (22.2% vs. 13.4%). Furthermore, on analysis of resection
specimens, NAT appears to reduce rates lymphovascular (43% vs. 52%) and perineural invasion (53%
vs. 80%) and increase the number of resections with N0 lymph node status (58% vs. 29%). These
results suggest the superiority of neoadjuvant therapy over upfront resection in reducing loco-regional
recurrences, overall recurrence, time to recurrence, and improving recurrence-free survival.
In the present review, subgroup analysis of recurrence rates in BRPC patients showed comparable
overall recurrence rates for BPRC in NAT and US. This is despite improved locoregional recurrence
with NAT in BRPC patients. This is in direct contrast to RPC where a significant overall recurrence
benefit was observed. In theory, the effect on RPC is surprising, however, this finding is similar to the
preliminary overall survival results from the Prep-02/JSAP-05 trial [60] in which NAT (gemcitabine and
S-1) performed better than immediate surgery for resectable PDAC with no significant survival benefit
in the BRPC group. Previous reports have highlighted significant discrepancies in the outcomes
following NAT for BRPC, and many authors attribute this finding to the failure to reach a consensus
with regards to a standardised definition [61,62]. The recently concluded PREOPANC trial showed
superior overall survival (OS) after preoperative chemo radiotherapy for BRPC and no significant
difference for resectable PDAC. Although multiple societies have endeavored to provide standardised
and, more importantly, validated definitions for PDAC. Assifi et al. reported that 40% of patients
diagnosed as BRPC using the AHPBA/SSO or SSAT definitions could be reclassified as RPC [63].
Indeed, the degree of vessel involvement [54] and the individual vessel involved [62] (portal vein,
hepatic artery, and or superior mesenteric artery) are on their own predictors of disease-free survival
and so variations in definitions will undoubtedly influence rates of recurrence. BRPC is known to
have higher rates of failure to achieve R0 resection, higher rates of occult metastases and requires
resection of more tissue [64]. BRPC may therefore represent a spectrum of disease rather than a single
entity, which may account for the conflicting results noted in these groups of patients in the literature.
The inclusion of this heterogeneity in the cohort may have contributed significantly to the lack of a
survival advantage with NAT. NAT is generally tolerated much better and morbidity following NAT
is considered independent of surgical morbidity [65]. Eighty-nine percent of patients successfully
completed NAT and underwent surgery in the review cohort, significantly higher than previously
reported, which may be contributed to by the high rates of RPC undergoing NAT. This is also far
superior to the 66% completed rate for adjuvant therapy reported in the literature [66].
Although chemotherapeutic subgroup analysis was limited, time to first recurrence and
the distribution of NAT-specific rates of organ-specific recurrence did not differ between agents.
Gemcitabine was the most frequently utilised NAT regimen in this cohort employed in nearly
60% of patients. However, following the results of the PRODIGE-24 trial [67] that demonstrated
superior disease free survival (DFS) in patients with FOLFIRINOX in comparison to Gemcitabine
for adjuvant therapy, FOLFIRINOX has become common practice. Indeed, combined NAT regimens
including Gemcitabine and FOLFIRINOX have shown a high response rate, and there is increasing
evidence to suggest that multi-agent NAT may suppress the recurrence of distant metastases [68,69];
however, to date, no trial has been published comparing FOLFIRINOX to other options. In the
current review, combination therapy was only employed in 23% of patients and 13% of patients were
administered FOLFIRINOX, suggesting the outcomes of NAT in this review may be more reflective
of other chemotherapeutic agents. The efficacy of FOLFIRINOX is the topic of current investigation.
The interim results of ESPAC-5F (ISRCTN89500674), Phase II RCT comparing immediate surgery with
neoadjuvant gemcitabine plus capecitabine or FOLFIRINOX or chemoradiotherapy in patients with
borderline resectable pancreatic cancer showed a significant survival benefit with NAT. The currently
ongoing PREOPANC2 trial (NTR7292, 2018-06-19), NorPACT-1 trial (NCT02919787) [70], SWOG S1505
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and PANACHE01-PRODIGE48 trial (NCT02959879) [71] may provide further evidence to support
NAT first strategy. Furthermore, additional radiotherapy to NAT remains uncertain [72,73]. Although
some reports suggest a significantly reduced rate of lymph node metastases and local recurrence with
neoadjuvant chemo-radiotherapy (NACRT) [38], the subgroup analysis from this review showed no
significant advantage with NACRT. Radiotherapy also has the added risk of increased postoperative
morbidity and may compromise surgical outcomes [38].
In the present review, NAT was also associated with reduced tumour diameter, lower rates of
perineural invasion, and lymphovascular invasion, leading to higher rates of R0 resection. This may
have contributed to the lower loco-regional recurrence rates in the NAT group. However, there were
comparable rates of distant recurrence between NAT and upfront resection groups, and this may be
contributed to by the lack of significant differences in lung or peritoneal recurrence rates between the
two groups. Whether the improved pathological parameters would translate into long term reduction
in recurrence rates and survival benefit is still a matter of debate. Even in patients achieving complete
pathological response after NAT, recurrence often occurs in half the patients [74].
There remain several limitations to the methodology of this review. This is a review of largely
retrospective articles with limited outcomes available for pairwise comparisons. There were obvious
discrepancies in the definitions of BRPC and LAPC that would have added significant heterogeneity
to the cohort. There also remains significant variability in the assessment of outcomes over time,
including methods of assessment for liver metastases following the increasing availability of magnetic
resonance imaging (MRI). This study also reported outcomes on solely patients who underwent
resection following NAT, thereby excluding those who failed to complete NAT from the final analysis.
An intention to treat analysis was abandoned due to the failure of most studies to report on the original
cohort. Furthermore, there remains some selection bias in favor of NAT therapy for improving rates of
liver metastases in view of the exclusion of NAT patients who ultimately failed to undergo resection.
This may have been due to multiple factors including local disease progression or distant metastases.
Patients were also recruited from various institutions around the world with differing perioperative
care protocols. The preoperative functional status of patients in each arm were also poorly reported
and were therefore underutilised to compare the cohorts at baseline. Propensity score matched data
was used where reported, however, this represented less than 20% of the cohort. The study data
was limited in its ability to report chemotherapy agent-specific outcomes, and FOLFIRINOX-based
chemotherapy regimens were uncommon despite there being a current trend towards its use in the
current day. Furthermore, the recurrence rate was reported with varying definitions from when it was
calculated. Significant deficiency was also identified regarding prospective data collection, blinded
assessment of outcomes, and power calculations. However, this is the first review to quantitatively
report the comparative recurrence outcomes including patterns of recurrence for this complex cohort
of patients.
5. Conclusions
This is the first quantitative analysis of recurrence patterns following NAT for PDAC. The review
found NAT improved rates of overall recurrence in RPC with lower locoregional and liver recurrence.
However, NAT did not appear to impact peritoneal or lung recurrence. NAT was also associated with a
reduced time to recurrence and recurrence free survival at both 2 and 5 years. The review is limited by
its largely retrospective dataset, and FOLFIRINOX-based chemotherapy regimens are poorly reflected
in the included studies. We await the results of currently ongoing RCTs and large prospective cohorts
to confirm the findings of this review and compare the relative efficacy of various NAT regimens.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/7/2132/s1,
Figure S1. Forest plot showing rate of locoregional (A) and distant (B) recurrence in studies reporting solely
either borderline resectable (BRPC) or resectable (RPC) pancreatic cancer for Neoadjuvant therapy (NAT) vs.
Up-front Surgery (US). A Manel-Haenszel random effects model with a Hartung-Knapp adjustment was used
for the meta-analysis of all outcomes. A Sidik-Jonkman estimator was utilised for tau2. Odds ratios (OR) are
shown with 95 percent confidence intervals (CI). Figure S2. Forest plot showing recurrence-free survival at (A)
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two-years and (B) five-years postoperatively following Neoadjuvant therapy (NAT) vs. Up-front Surgery (US).
A Manel-Haenszel random effects model with a Hartung-Knapp adjustment was used for the meta-analysis of all
outcomes. A Sidik-Jonkman estimator was utilised for tau2. Odds ratios (OR) are shown with 95 percent confidence
intervals (CI). Figure S3. Forest plot showing overall recurrence rates in articles reporting (A) preoperative
resectability and (B) preoperative chemoradiotherapy subgroups following Neoadjuvant therapy (NAT) vs.
Up-front Surgery (US). A Manel-Haenszel random effects model with a Hartung- Knapp adjustment was used for
the meta-analysis of all outcomes. A Sidik-Jonkman estimator was utilised for tau2. Odds ratios (OR) are shown
with 95 percent confidence intervals (CI). Figure S4. Forest plot showing (A) Liver, (B) Lung and (B) Peritoneal
recurrence rates following Neoadjuvant therapy (NAT) vs. Up-front Surgery (US). A Manel-Haenszel random
effects model with a Hartung-Knapp adjustment was used for the meta-analysis of all outcomes. A Sidik-Jonkman
estimator was utilised for tau2. Odds ratios (OR) are shown with 95 percent confidence intervals (CI). Figure S5.
Forest plot showing mean tumor diameter in mm following Neoadjuvant therapy (NAT) vs. Up-front Surgery
(US). A Manel-Haenszel random effects model with a Hartung-Knapp adjustment was used for the meta-analysis
of all outcomes. A Sidik-Jonkman estimator was utilised for tau2. Standard Mean Differences (SMD) are shown
with 95 percent confidence intervals. Figure S6. Forest plot showing (A) Poor Tumor differentiation at the time
of surgery (B) perineural and (A) Lymphovascular involvement rates following Neoadjuvant therapy (NAT) vs.
Up-front Surgery (US). A Manel-Haenszel random effects model with a Hartung-Knapp adjustment was used for
the meta-analysis of all outcomes. A Sidik-Jonkman estimator was utilised for tau2. Odds ratios (OR) are shown
with 95 percent confidence intervals (CI). Figure S7. Forest plot showing (A) N0 Status and (B) R0 Resection rates
following Neoadjuvant therapy (NAT) vs. Up-front Surgery (US). A Manel-Haenszel random effects model with
a Hartung-Knapp adjustment was used for the meta-analysis of all outcomes. A Sidik-Jonkman estimator was
utilised for tau2. Odds ratios (OR) are shown with 95 percent confidence intervals (CI). Figure S8. Funnel plots
for all meta-analysis outcomes including (A) Tumor Size, (B) N0 Nodal Status, (C) Poor tumor differentiation,
(D) Perineural invasion, (E) Lymphovascular invasion, (F) R0 Resection, (G) Overall recurrence, and (H) Recurrence
free survival. Table S1. Patient characteristics among all studies included within the meta-analysis. Table S2.
Pathological outcomes in all studies within the meta-analysis. Table S3. Resectability and eoadjuvant therapy
of all patients who underwent resection included in the quantitative analysis within this meta-analysis. Table
S4. Results of the mixed-effects meta-regression to identify potential predictors of overall recurrence in the (A)
neoadjuvant therapy (NAT) and (B) up-front surgery (US) groups. Variables were included in the mixed effects
model if they were significantly different between NAT and US where differences were identified on meta-analysis
and with an incidence of ≥ three for categorical variables. Table S5. (A) The MINORS criteria [27] scores for all
non-randomised studies included in the review and (B) Cochranes Risk of bias tool for randomised trials.
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Appendix A
Table A1. Literature search strategy.
1 Adjuvant. mp. or exp Chemotherapy, Adjuvant/or exp Chemoradiotherapy, Adjuvant/
2 exp Neoadjuvant Therapy/or neoadjuvant.mp.
3 Chemo *.mp.
4 Pancreatic Cancer.mp. or exp Pancreatic Neoplasms/
5 exp Carcinoma, Pancreatic Ductal/or Pancreatic adenocarcinoma.mp.
6 Pancreatectomy.mp. or exp Pancreatectomy/
7 Pancreatectomy/or Pancreatic Resection.mp.
8 pancreaticoduodenectomy.mp. or exp Pancreaticoduodenectomy/
9 Whippl *.mp.
10 exp Recurrence/or exp Neoplasm Recurrence, Local/or Recurrence.mp.
11 Relapse.mp. or exp Recurrence/
12 Failure.mp. or exp Treatment Failure/
Strategy: (1 OR 2 OR 3) AND [(4 OR 5) AND (6 OR 7 OR 8 OR 9)] AND (11 OR 12). Explode (exp) and relevant
medical subjecting headings (MeSH) were employed to further expand the results of each individual query in order
to capture all potentially relevant articles. * Denotes a wildcard search for multiple search terms.
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